Compare IZEA & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | CPHI |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.9M | 61.6M |
| IPO Year | 2010 | 2008 |
| Metric | IZEA | CPHI |
|---|---|---|
| Price | $3.15 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.0K | ★ 5.7M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,099,695.00 | $4,144,268.00 |
| Revenue This Year | $20.81 | N/A |
| Revenue Next Year | $14.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $0.38 |
| 52 Week High | $5.86 | $19.19 |
| Indicator | IZEA | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 48.49 |
| Support Level | N/A | $0.52 |
| Resistance Level | $3.79 | $1.43 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 18.88 | 21.69 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.